These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

289 related items for PubMed ID: 8879902

  • 1. Pharmacoeconomic analysis of oral therapies for onychomycosis: a US model.
    Marchetti A, Piech CT, McGhan WF, Neugut AI, Smith BT.
    Clin Ther; 1996; 18(4):757-77; discussion 702. PubMed ID: 8879902
    [Abstract] [Full Text] [Related]

  • 2. Pharmacoeconomic analysis of ciclopirox nail lacquer solution 8% and the new oral antifungal agents used to treat dermatophyte toe onychomycosis in the United States.
    Gupta AK.
    J Am Acad Dermatol; 2000 Oct; 43(4 Suppl):S81-95. PubMed ID: 11051137
    [Abstract] [Full Text] [Related]

  • 3. Pharmacoeconomic analysis of oral antifungal therapies used to treat dermatophyte onychomycosis of the toenails. A US analysis.
    Gupta AK.
    Pharmacoeconomics; 1998 Feb; 13(2):243-56. PubMed ID: 10178650
    [Abstract] [Full Text] [Related]

  • 4. Treatment of dermatophyte toenail onychomycosis in the United States. A pharmacoeconomic analysis.
    Gupta AK.
    J Am Podiatr Med Assoc; 2002 May; 92(5):272-86. PubMed ID: 12015408
    [Abstract] [Full Text] [Related]

  • 5. Economic analysis of oral and topical therapies for onychomycosis of the toenails and fingernails.
    Casciano J, Amaya K, Doyle J, Arikian S, Shear N, Haspel M, Kahler K.
    Manag Care; 2003 Mar; 12(3):47-54. PubMed ID: 12685377
    [Abstract] [Full Text] [Related]

  • 6. A cost/efficacy analysis of oral antifungals indicated for the treatment of onychomycosis: griseofulvin, itraconazole, and terbinafine.
    Angello JT, Voytovich RM, Jan SA.
    Am J Manag Care; 1997 Mar; 3(3):443-50. PubMed ID: 10173095
    [Abstract] [Full Text] [Related]

  • 7. A multinational pharmacoeconomic analysis of oral therapies for onychomycosis. The Onychomycosis Study Group.
    Arikian SR, Einarson TR, Kobelt-Nguyen G, Schubert F.
    Br J Dermatol; 1994 Apr; 130 Suppl 43():35-44. PubMed ID: 8186141
    [Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness analysis for onychomycosis therapy in Canada from a government perspective.
    Einarson TR, Arikian SR, Shear NH.
    Br J Dermatol; 1994 Apr; 130 Suppl 43():32-4. PubMed ID: 8186140
    [Abstract] [Full Text] [Related]

  • 9. [Oral treatment of onychomycosis of the toe nails; comparison of cost-effectiveness of griseofulvin, itraconazole, ketoconazole and terbinafine].
    Bergman W, Rutten FF.
    Ned Tijdschr Geneeskd; 1994 Nov 19; 138(47):2346-50. PubMed ID: 7969635
    [Abstract] [Full Text] [Related]

  • 10. Economic evaluation of antifungal agents in the treatment of toenail onychomycosis in Germany.
    Van Doorslaer EK, Tormans G, Gupta AK, Van Rossem K, Eggleston A, Dubois DJ, De Doncker P, Haneke E.
    Dermatology; 1996 Nov 19; 193(3):239-44. PubMed ID: 8944348
    [Abstract] [Full Text] [Related]

  • 11. Cost effectiveness of continuous terbinafine compared with intermittent itraconazole in the treatment of dermatophyte toenail onychomycosis: an analysis of based on results from the L.I.ON. study. Lamisil versus Itraconazole in Onychomycosis.
    Jansen R, Redekop WK, Rutten FF.
    Pharmacoeconomics; 2001 Nov 19; 19(4):401-10. PubMed ID: 11383756
    [Abstract] [Full Text] [Related]

  • 12. Terbinafine: a review of its use in onychomycosis in adults.
    Darkes MJ, Scott LJ, Goa KL.
    Am J Clin Dermatol; 2003 Nov 19; 4(1):39-65. PubMed ID: 12477372
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of itraconazole, terbinafine, fluconazole, griseofulvin and ketoconazole in the treatment of Scopulariopsis brevicaulis causing onychomycosis of the toes.
    Gupta AK, Gregurek-Novak T.
    Dermatology; 2001 Nov 19; 202(3):235-8. PubMed ID: 11385230
    [Abstract] [Full Text] [Related]

  • 14. Cost-effectiveness of two new treatments for onychomycosis: an analysis of two comparative clinical trials.
    Bootman JL.
    J Am Acad Dermatol; 1998 May 19; 38(5 Pt 3):S69-72. PubMed ID: 9594941
    [Abstract] [Full Text] [Related]

  • 15. Oral therapeutic agents in fungal nail disease.
    Roberts DT.
    J Am Acad Dermatol; 1994 Sep 19; 31(3 Pt 2):S78-81. PubMed ID: 8077514
    [Abstract] [Full Text] [Related]

  • 16. A questionnaire study on the management of onychomycosis: a Canadian perspective.
    Gupta AK, Shear NH.
    Int J Dermatol; 1998 Jun 19; 37(6):457-60. PubMed ID: 9646138
    [Abstract] [Full Text] [Related]

  • 17. Pharmacoeconomic analysis of the new oral antifungal agents used to treat toenail onychomycosis in the USA.
    Gupta AK, Lambert J.
    Int J Dermatol; 1999 Sep 19; 38 Suppl 2():53-64. PubMed ID: 10515529
    [No Abstract] [Full Text] [Related]

  • 18. [Oral treatment of onychomycosis of the toe nails; comparison of cost effectiveness of griseofulvin, itraconazole, ketoconazole and terbinafine].
    Neumann HA.
    Ned Tijdschr Geneeskd; 1995 Jul 01; 139(26):1350-1. PubMed ID: 7617054
    [No Abstract] [Full Text] [Related]

  • 19. The use of oral antifungal agents to treat onychomycosis.
    Gupta AK, Ryder JE.
    Dermatol Clin; 2003 Jul 01; 21(3):469-79, vi. PubMed ID: 12956199
    [Abstract] [Full Text] [Related]

  • 20. Clinical and economic factors in the treatment of onychomycosis.
    Einarson TR, Gupta AK, Shear NH, Arikian S.
    Pharmacoeconomics; 1996 Apr 01; 9(4):307-20. PubMed ID: 10160105
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.